FRANKA Ventures -
a founders one-of-a-kind companion

Because we are serial entrepreneurs ourselves, with a track record of successful exits and the establishment of an international Billion-Euro Corporation and industry leader as DAX CEO on our CVs, we are exceptionally experienced mentors for all founders. Today, our focus is on Lifesciences, Healthcare, Healthtech & Medtech. However, in the past, we have also been active in other industries, always with a strong tech focus. We open up our unparalleled network to you, with access to CEOs, high-profile family offices, entrepreneurs and politicians. We are unusual, unconventional and enjoy working with people who want to make the difference.

FRANKA primarily invests in seed and early-stage companies, with investments ranging from €50k to €500k, and occasionally orchestrates larger rounds alongside our network and institutional partners.

Here is a selection of past and current investments and holdings of Francesco and Kai-Erik:

bildinx.com

Probably the first German PropTech, co-founded in 2012 by Kai-Erik Ströbel, was acquired by an insurance group and never saw the light of day in the real estate world. For whatever reason. A few years later, PropTechs sprang up like mushrooms and still do. The founding team had truly shown foresight.

FUTUROMUNDO Conference & Festival, Stuttgart

A new live brand and home of a movement that creates and celebrates the future. With streams such as education, creativity, innovation and entrepreneurship

Gimel – The Antidote to Abusive AI and Fake IDs

Gimel ID is the world`s most secure identity. It facilitates the Gimel open-source platform for secure identities and practical AI control.

Marshall Group, Stockholm 

An iconic brand in the musician community was kissed in 2010 by the ingenious Swedish entrepreneurs of zoundindustries. They became a global champion for stylish audio electronics and merged in 2023 to form the new Marshall Group. The success story continues with brands such as Marshall Headphones, Urbanears and adidas headphones. In 2024 Marshall was once again the main sponsor of South by Southwest Festival in Austin, Texas. In 2025, 80% of the shares in the Marshall Group were sold at a valuation of €1.4 billion.

Healthcare

Introducing The DeMeo Future of Health Collective

a curated portfolio of elite healthtech and life science startups united by a single, audacious vision: to shape the future of healthcare.

This vision is grounded in the strategic expertise of Francesco de Meo, who spent two decades building Europe’s largest private hospital group. By seamlessly integrating the technologies and talents of our portfolio companies, we are creating a unique, next-generation healthcare platform that is greater than the sum of its parts. The time for evolution is now. The future of health starts here.

Aimax.Care

Using AI to better channel patient flows and relieve chronically overcrowded medical emergency departments

NEW: Aniva Health

Aniva Health is a precision-health platform that uses a single blood draw to analyze over 100 biomarkers and generate a personalized, data-driven health blueprint.

By combining continuous testing, AI-powered insights, and tailored lifestyle and supplement recommendations, Aniva enables users to detect risks early and take proactive control of their long-term health.

The company is building a scalable operating system for preventive healthcare—shifting the model from reactive treatment to continuous optimization.

DataVaccinator

The solutions offered by DataVaccinator are particularly relevant for areas where sensitive data must be protected while still being usable, such as:
 
• Healthcare / medical data
• Financial data
• IoT data (Internet of Things)
• Analytics & AI platforms
 
The technology enables organizations to share or analyze data collaboratively without compromising data protection or security.

NuAcRes

Industry: Biotechnology / Pharmaceutical drug development
Focus: Development of novel immunotherapies targeting solid tumors (e.g. breast, lung, and colorectal cancer).
Target Market: Immuno-oncology, specifically the treatment of solid tumors—an area with high unmet medical need and significant market potential.